Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-12-30 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于部分董事、监事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the resignation of several board members and supervisors. It details the resignation letters received, the impact on the board composition, and the company's plan to fill the vacancies. There is no financial data, no mention of annual or quarterly reports, no audit information, no voting results, and no other report types. The content clearly relates to changes in the company's board and senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication but a direct announcement of management changes.
2022-12-30 Chinese
昆药集团关于华立医药及华立集团协议转让公司股份完成过户登记的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of share transfer registration between parties involving the company's shares. It details the shareholding changes, references prior announcements, and includes official confirmation documents. The content is focused on notifying the market and shareholders about the change in share ownership and control, rather than presenting financial data, management discussion, or detailed reports. The document length is short (1644 characters) and it serves as a formal notification of a share transfer event. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2022-12-30 Chinese
昆药集团关于获得政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the receipt of government subsidy funds totaling approximately 55.7 million yuan. It details the amounts, sources, and accounting treatment of these subsidies, including their expected impact on the company's profit for the year 2022. The document explicitly states that the final accounting treatment and impact will be confirmed by the auditor's annual audit results. The document length is 3704 characters, which is relatively short and primarily serves as a disclosure or announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about government subsidies affecting the company's financials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-27 Chinese
昆药集团2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the company's 2022 second extraordinary general meeting of shareholders. It details the meeting date, attendance, voting results, and legal witness statements. It does not contain financial statements or detailed financial analysis but reports the official voting outcomes and meeting proceedings. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting results, not a full report or presentation.
2022-12-23 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2022年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion from a law firm regarding the convening, attendance, and voting procedures of Kunming Pharmaceutical Group Co., Ltd.'s 2022 second extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting and resolutions passed, including the change of accounting firm. The document does not contain financial statements or detailed financial data but focuses on the legal aspects of the shareholders' meeting and voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting outcomes and meeting procedures.
2022-12-23 Chinese
昆药集团关于华润三九收购昆药集团事项获国务院国资委批复的公告
M&A Activity Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the approval by the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) for China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. to acquire controlling shares of Kunming Pharmaceutical Group. It details the transaction background, regulatory approvals, and next steps including shareholder meeting and compliance procedures. The document is a formal announcement of a merger/acquisition transaction approval, not the full merger filing or detailed merger documents. It is not a full annual or interim report, nor a financial statement or earnings release. The content fits the category of M&A Activity announcements related to merger proposals or takeover bids.
2022-12-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.